Kura Oncology Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect the three nominees for Class III director (Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D.) to serve three-year terms expiring at the 2029 Annual Meeting.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit Committee’s appointment of Ernst & Young LLP as Kura’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Vote on the Compensation of our Named Executive Officers (Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory approval of the compensation paid to the Company’s named executive officers as disclosed in the proxy statement.

   More detail

   This advisory Say-on-Pay proposal asks stockholders to endorse, on a non-binding basis, the Company’s overall executive compensation for the named executive officers as disclosed in the proxy statement. Management frames the program as pay-for-performance with heavy emphasis on at-risk compensation (annual cash incentives and long-term equity), alignment with stockholder interests, and use of independent advisors and peer benchmarking; the Board commits to consider stockholder feedback. The vote is advisory and does not change contractual obligations; however, the Compensation Committee and the Board will consider the outcome in future compensation decisions. Company-specific context: Kura transitioned in 2025 from R&D-stage to commercial following FDA approval and commercialization of KOMZIFTI, materially increasing the Company’s operational complexity and headcount (35% workforce growth in 2025), which management cites as a rationale for competitive compensation and equity usage. The Compensation Committee used independent consultants and a peer group to set pay levels and retains discretion over final awards; it emphasizes long-term equity incentives (options, RSUs, PSUs) to retain and align executives. Management notes strong prior stockholder support for its compensation approach (e.g., ~98% support in the most recent say-on-pay) and maintains clawback and other governance safeguards. Key investor governance considerations include the non-binding nature of the vote, magnitude and structure of equity awards (dilution, burn rates, and fungible share counting), change-in-control and severance protections, and compensation recoupment policies. For institutional investors assessing the proposal, the question is whether pay design and disclosed outcomes reasonably align compensation with the Company’s recent FDA approval, commercial launch execution, and long-term clinical and commercial milestones. The Board recommends FOR; a negative vote would signal discontent and likely trigger further engagement and potential design changes, while a strong FOR would validate current policies and support management continuity through the commercial transition.

4. 4

   Advisory Vote on the Frequency of Stockholder Advisory Votes on Executive Compensation

   ManagementBoard: FOR

   Non-binding, advisory vote to indicate whether stockholders prefer the Company to hold future Say-on-Pay votes every one, two, or three years (Board recommends One Year).

   More detail

   This advisory frequency proposal asks stockholders to indicate their preferred cadence for future say-on-pay votes (one, two, or three years). Management recommends an annual (one-year) frequency, arguing that regular annual votes permit timely stockholder feedback and align with the Company’s rapid operating cadence as it transitions to commercial operations following the 2025 KOMZIFTI approval and launch. The vote is non-binding but influential: the Compensation Committee and Board will consider results when setting future policy. For investors, the core trade-off is responsiveness (annual votes offer frequent engagement signals and accountability) versus potential administrative duplication (less frequent votes reduce recurring administrative processes). Company-specific context supports annual voting — Kura has undergone material operational change and increased executive compensation complexity (larger workforce, launch expenditures, milestone-driven incentives) that argue for frequent shareholder input. Institutional governance advisors often recommend annual votes for companies in transformative phases; however, some investors prefer triennial votes where long-term compensation cycles dominate. If no frequency receives a majority, the Company will treat the option with the plurality as the preferred frequency, per the proxy. The Board’s recommendation for one year reflects a preference for continued active engagement during a period of significant execution risk and opportunity.

5. 5

   Approval of an Amendment to the Amended and Restated 2014 Equity Incentive Plan

   ManagementBoard: FOR

   Approve the Board-approved amendment to the 2014 Equity Incentive Plan to increase the share reserve by 6,500,000 shares (resulting in a maximum of 41,077,686 shares) and related changes (including an ISO limit increase).

   More detail

   This management proposal requests stockholder approval to increase the share reserve under the Company’s 2014 Equity Incentive Plan by 6.5 million shares (to a total of 41,077,686 shares) and to increase the ISO issuance limit. Management argues that the new reserve is necessary to continue granting equity awards to recruit, retain and motivate employees and directors as Kura scales its commercial organization following FDA approval and launch of KOMZIFTI in 2025. The Compensation Committee supports the increase after reviewing the Company’s growth in headcount (35% in 2025), historical grant levels, burn rates and full-dilution metrics; management presents average full-dilution (~22–24%), gross burn (~5–6%), and net burn (~4–4.5%) figures as evidence of measured plan usage. The amendment includes several stockholder-protective features: no annual evergreen; prohibition on repricing or cancelling underwater awards for cash or new awards without stockholder approval; limited share recycling; clawback/recoupment provisions to comply with Section 10D-1; and a non-liberal change-in-control definition. From a governance and valuation perspective, institutional investors will weigh the dilution impact (increase in share count and prospective dilution) against the operational need to staff a commercial launch and the board’s governance mitigants. The Board frames the requested amount as reasonable relative to prior grant practices and peer benchmarks and points to prior high shareholder support for equity amendments (approx. 80% historically). For sophisticated evaluation, key factors are the proposed share count relative to market capitalization and outstanding options, the Company’s historical burn/dilution discipline, the mix of option vs full-value awards (1.44 fungible share-counting for full-value awards), and whether the plan’s governance features mitigate potential agency concerns; a favorable vote would enable continued equity-based retention and incentive programs, while a negative vote would constrain the board’s ability to grant market-competitive awards and could increase retention risk during commercialization.

6. 6

   Approval of an Amendment to the 2015 Employee Stock Purchase Plan

   ManagementBoard: FOR

   Approve the Board-approved amendment to the 2015 Employee Stock Purchase Plan to increase the share reserve by 2,500,000 shares (bringing the maximum to 3,404,425 shares).

   More detail

   This management proposal requests shareholder approval to add 2.5 million shares to the Company’s Employee Stock Purchase Plan, restoring and expanding the reserve after the prior evergreen provision expired. Management frames the ESPP as a broad-based employee ownership and retention tool (approximately 261 employees eligible as of March 31, 2026) and notes that the Amended ESPP uses an 85% of market look-back pricing and six-month offering periods, which are typical ESPP design features. The requested increase (to 3,404,425 shares) is positioned as modest relative to total outstanding shares and necessary to allow continued employee participation as the Company grows post-commercial launch. Governance considerations include limits on aggregate participation per employee, the requirement for stockholder approval for material amendments, and the Company’s representation that the plan is intended to comply with Section 423 of the Internal Revenue Code. Investors assessing the amendment should consider expected employee uptake, dilution impact relative to market cap, the plan’s look-back discount and offering cadence, and the Company’s historical participation rates; management’s recommendation for FOR reflects the view that the ESPP supports retention and alignment during a critical commercial scaling period.

Upcoming shareholder meetings at Kura Oncology Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Kura Oncology Inc 2026 annual meeting?

Kura Oncology Inc (KURA) holds its 2026 annual shareholder meeting on Thursday, June 4, 2026.

What is the record date for the Kura Oncology Inc 2026 meeting?

The record date for the Kura Oncology Inc 2026 meeting is Monday, April 6, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Kura Oncology Inc's 2026 meeting?

The board is presenting 3 director nominees at the Kura Oncology Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Kura Oncology Inc 2026 meeting?

Shareholders will vote on 6 proposals at the Kura Oncology Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.